XOMA Corporation Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Financial Statement Detail (Tables)

Condensed Consolidated Financial Statement Detail (Tables)

6 Months Ended

Jun. 30, 2014

Condensed Consolidated Financial Statement Detail [Abstract]

Outstanding securities considered anti-dilutive

The following table shows the total outstanding securities considered anti-dilutive and therefore excluded from the computation of diluted net loss per share (in thousands):

	Three Months Ended June 30,				Six Months Ended June 30,
	2014		2013		2014		2013
Common stock options and restricted stock units		7,939		7,346		6,576		7,084
Warrants for common stock		1,910		16,176		1,910		16,176
Total		9,849		23,522		8,486		23,260

Schedule of Net Income Loss and Weighted Average Shares Outstanding

For the three and six months ended June 30, 2014, the following is a reconciliation of the numerators and denominators of the basic and diluted net loss per share of common stock (in thousands):

	Three Months Ended June 30,			Six Months Ended June 30,
	2014			2014
Numerator
Net loss
Basic	$	(11,897	)	$	(16,584	)
Adjustment for revaluation of contingent warrant liabilities		(7,616	)		(27,150	)
Diluted	$	(19,513	)	$	(43,734	)
Denominator
Weighted average shares outstanding used for basic net loss per share		106,927			106,545
Effect of dilutive warrants		7,199			8,503
Weighted average shares outstanding and dilutive securities used for diluted net income per share		114,126			115,048

Accrued liabilities

Accrued liabilities consisted of the following at June 30, 2014 and December 31, 2013 (in thousands):

	June 30, 2014		December 31, 2013
Accrued payroll and other benefits	$	2,698	$	3,009
Accrued management incentive compensation		2,123		4,386
Other		1,568		2,539
Total	$	6,389	$	9,934